Recommended Topic Related To:

Sylatron

"This week the U.S. Food and Drug Administration approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage).

"...

Sylatron

Sylatron

INDICATIONS

SYLATRON™ is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.

DOSAGE AND ADMINISTRATION

Recommended Dose

  • 6 mcg/kg/week subcutaneously for 8 doses, followed by 3 mcg/kg/week subcutaneously for up to 5 years.
  • Premedicate with acetaminophen 500 to 1000 mg orally 30 minutes prior to the first dose of SYLATRON and as needed for subsequent doses.

Dose Modification

Guidelines for Dose Modification provided below are based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE Version 2.0).

  • Permanently discontinue SYLATRON for:
    • Persistent or worsening severe neuropsychiatric disorders
    • Grade 4 non-hematologic toxicity
    • Inability to tolerate a dose of 1 mcg/kg/wk
    • New or worsening retinopathy
  • Withhold SYLATRON dose for any of the following:
  • Resume dosing at a reduced dose (see Table 1) when all of the following are present:
    • Absolute Neutrophil Count (ANC) ≥ 0.5x109/L
    • Platelet Count (PLT) ≥ 50x109/L
    • ECOG PS 0-1
    • Non-hematologic toxicity has completely resolved or improved to Grade 1

TABLE 1: SYLATRON Dose Modifications

Starting Dose Dose Modifications for Doses 1 to 8
6 mcg/kg/week First Dose Modification: 3 mcg/kg/week
Second Dose Modification: 2 mcg/kg/week
Third Dose Modification: 1 mcg/kg/week
Permanently discontinue if unable to tolerate 1 mcg/kg/week
Starting Dose Dose Modifications for Doses 9 to 260
3 mcg/kg/week First Dose Modification: 2 mcg/kg/week
Second Dose Modification: 1 mcg/kg/week
Permanently discontinue if unable to tolerate 1 mcg/kg/week

Preparation and Administration

Reconstitute SYLATRON with 0.7 mL of Sterile Water for Injection USP.

Upon reconstitution, the final concentration of SYLATRON will be

    • 40 mcg per each 0.1 mL for vials containing 296 mcg of SYLATRON
    • 60 mcg per each 0.1 mL for vials containing 444 mcg of SYLATRON
    • 120 mcg per each 0.1 mL for vials containing 888 mcg of SYLATRON
  • Swirl gently to dissolve the lyophilized powder. DO NOT SHAKE.
  • Visually inspect the solution for particulate matter and discoloration prior to administration. Discard if solution is discolored, cloudy, or if particulates are present.
  • Do not withdraw more than 0.5 mL of reconstituted solution from each vial.
  • Administer SYLATRON subcutaneously. Rotate injection sites.
  • If reconstituted solution is not used immediately, store at 2°-8°C (36°-46°F) for no more than 24 hours. Discard reconstituted solution after 24 hours. DO NOT FREEZE.
  • For single-use only. DISCARD ANY UNUSED PORTION.

HOW SUPPLIED

Dosage Forms And Strengths

  • 296 mcg lyophilized powder per single-use vial
  • 444 mcg lyophilized powder per single-use vial
  • 888 mcg lyophilized powder per single-use vial

Storage And Handling

Each SYLATRON Package Contains:  
A box containing one 296 mcg vial of SYLATRON powder and one 1.25 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-1388-01)
A box containing one 444 mcg vial of SYLATRON powder and one 1.25 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-1287-02)
A box containing one 888 mcg vial of SYLATRON powder and one 1.25 mL vial of Sterile Water for Injection, USP, 2 B-D Safety Lok syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-1312-01)
Each SYLATRON PACK 4 Contains:  
A box containing four 296 mcg vials of SYLATRON powder and four 1.25 mL vials of Sterile Water for Injection, USP, 8 B-D Safety Lok syringes with a safety sleeve and 8 alcohol swabs. (NDC 0085-1388-02)
A box containing four 444 mcg vials of SYLATRON powder and four 1.25 mL vials of Sterile Water for Injection, USP, 8 B-D Safety Lok syringes with a safety sleeve and 8 alcohol swabs. (NDC 0085-1287-03)
A box containing four 888 mcg vials of SYLATRON powder and four 1.25 mL vials of Sterile Water for Injection, USP, 8 B-D Safety Lok syringes with a safety sleeve and 8 alcohol swabs. (NDC 0085-1312-02)

Storage

SYLATRON should be stored at 25°C (77°F); excursions permitted to 15°-30°C (59-86°F) [see USP Controlled Room Temperature]. DO NOT FREEZE.

Manufactured by: Schering Corporation, a subsidiary of MERCK & CO., INC., Whitehouse Station, NJ 08889, USA. Revised: 12/2012

Last reviewed on RxList: 1/23/2013
This monograph has been modified to include the generic and brand name in many instances.

A A A

Sylatron - User Reviews

Sylatron User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Sylatron sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.

Health Resources
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations